The article presents a case with diagnosed Hodgkin disease (HD) during pregnancy. The aim of this case study was to present diagnostic possibilities in determining HD stage during pregnancy and therapeutic dilemmas. The incidence of HD during pregnancy is 3.2% of all cases with this malignant hematological disorder. The treatment of this disease during pregnancy depends on disease-related factors, pregnancy-related factors, as well as possible implications for fetal morbidity and mortality. The need of analysis of the nature of the disease during pregnancy indicates examination of a larger series of pregnant women with HD and the drawn conclusions affect the decision whether chemotherapy treatment should start immediately or it should be postponed for after delivery.
Introduction
Malignant lymphomas are the fourth most frequent malignant disease during pregnancy and the most common type of lymphoma during pregnancy is Hodgkin disease (HD). The incidence of HD in pregnancy is 3.2% of all patients with HD or 1 case on 1000 up to 1 on 6000 deliveries [1] . HD is a malignant disease which is believed to be curable with first line of conventional chemotherapy, especially in its early stage. The rate of 5 years overall survival of HD patient grade I and II is 90% to 95%. The rest of 10% to 15% are patients with relapsed or refractory disease that has not responded to primary treatment with chemotherapy. For patients with advanced disease stage 5 years survival is increased from 80% to 90%. The decision on the timing of initiation of treatment with chemotherapy during pregnancy is correlated with the clinical presentation of the disease, the initial stage of the disease, histological type, factors related to pregnancy, the maturity of the fetus and the possible implications of starting treatment of the fetus [2] . Treatment
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Aleksandra Pivkova Veljanovska, University Clinic of Hematology, "Vodnjanska", 17, 1000 Skopje, R. Macedonia; E-mail: aleksandrapivkova@yahoo.com of HD during pregnancy is individualized. Starting chemotherapy during pregnancy is most common in the third and fourth trimester of pregnancy, while radiation at this stage of pregnancy is considered to be contraindicated because of the possibility of late teratogenic effects [3] . The data for the start of chemotherapy in the first trimester of pregnancy are scarce and are associated with high morbidity and mortality of pregnant women and the fetus [4] . The aim of this paper is to present the case of a pregnant woman with HD, diagnostic possibilities in staging the disease and identifying the nature of HD during pregnancy as a necessary factor in determining the timing for starting treatment with chemotherapy.
Case report
The paper presents the case of a 42-year-old woman, first time pregnant, in 20 weeks of pregnancy, hospitalized at the University Clinic of Hematology in terms of daily hospital in March 2012 due to the occurrence of cervical lymphadenopathy. On physical examination at admission increased cervical lymph glands were observed; left neck dimension 3.0 x 3.0 cm, and two left supraclavicular glands dimension 2.0x2.0 cm. The physical examination was impossible to determine hepatosplenomegaly which is why the patient was indicated for ultrasonography of abdominal organs. Hepatosplenomegaly was detected with ultrasonic examination, and B symptoms were not present in the clinical presentation of lymphadenopathy. Prenatal evaluation and ultrasonography performed at the University Clinic of Gynecology and Obstetrics were neat and suggested the existence of a single pregnancy with adequate growth and development of the fetus according to the gestational week. The patient had seven years of previous gynecological obstetric history with treating infertility. Surgical biopsy of cervical lymph gland in surgical operating room under general anesthesia was performed. Pathological finding of Hodgkin's disease was received; classic nodular sclerosis disease; the immunohistochemical analysis of CD30 + CD15 + CD20-, CD79-, CD3-, CD10-, Bcl6 -, bcl2 + Ki67 60%. Bone marrow biopsy showed no infiltration by HD in the bone marrow. Computerized tomography (CT) of the lungs and mediastinum revealed presence of polycyclic lobulated tumor mass in the right lung projection in retrosternal and upper me-diastinum. Lung parenchyma was with normal architecture. The patient initially underwent cardiologic examination with echocardiography, which found a good kinetics and function of the myocardium (70% ejection rate). According to the WHO classification and Ann Arbor classification system stages and its modifications for HD, the patient was classified as unconfirmed II/III A stage. The patient gave a written statement for refusal of both pregnancy termination and application of chemotherapy. Treatment with corticosteroids (Prednisone 40 mg/day) started and was planned to continue until delivery. Fetal growth and development were monitored every 4 weeks by ultrasonography. During February 2012 amniocentesis was performed and revealed settled chromosomal karyotype (45XY). In June 2012, after the normal delivery of a healthy baby boy (2750 kg, Apgar 8-9) in 37 weeks with oxitocyne induction, treatment with ABVD chemotherapy in 12 doses or 6 cycles of an interval of 14 days started. The second dose of application protocol to treat intense life-threatening allergic reaction was detected to Bleocin, which resulted in the further exclusion from therapy and was extended by another 10 doses of chemotherapy after AVD protocol. After application of the third cycle of chemotherapy, clinical withdrawal was recorded in the local finding of cervical lymphadenopathy. Initial laboratory findings and chemotherapy treatment protocol is shown in Table 1 and 2. In November 2012 treatment ended with a total of 12 doses of chemotherapy. In January 2013 positron emission tomography with computed tomography (PET/CT) was performed that confirmed the presence of complete remission (CR) without pathological FDG accumulation. The patient was advised to stop lactation of the newborn. The patient is now 2.5 years after completion of treatment and is still in CR.
Discussion
HD is a malignancy with identical clinical presentation and pathohistology in pregnant women as in the general population at that age. In terms of pathohistology, the most common type of HD in pregnancy is nodular sclerosis. There are restrictions on visualization methods such as radiography and computed tomography-based release of ionizing radiation, which could have a direct or indirect impact on the development of the fetus. Therefore, magnetic resonance imaging (MRI) is a method of choice for visualization during pregnancy [4] . PET/ CT is the method of choice and is recommended after the initial treatment. Pregnant women with HD are recommended to have intensive prenatal monitoring prediction of prematurity and possible chromosomal abnormalities of the fetus. In the presented patient with HD, diagnosis and stage of disease were provided by CT and abdominal ultrasonography, as well as a history and physical examination data. From maternity obstetric monitoring no signs of preterm labor or birth of a child with reduced body weight were revealed. The presence of chromosomal abnormalities was excluded by amniocentesis, which recorded normal karyotype. Indications for starting treatment for HD during pregnancy are: presence of local symptoms due to progressive or bulky nodal disease, symptomatic infradiaphragmal disease, presence of B symptoms, increased values of LDH, ESR, hypoalbuminemia, extranodal presence of symptomatic disease and cytopenia due to bone marrow infiltration with HD, thrombocytopenia, effusions, hypersplenism, etc. Upon diagnosis of HD during the second half of pregnancy, starting a treatment with chemotherapy with normal doses of chemotherapy drugs is recommended without risk of poor fetal outcome. Avoiding treatment with intensive chemotherapy at diagnosis of HD and pregnancy in the first trimester of pregnancy is recommended due to the possibility of high morbidity of the fetus and the mother. Radiotherapy is generally not recommended as a method of treatment during pregnancy. If indicated it is postponed until after delivery. ABVD chemotherapy protocol is the treatment of choice in HB during pregnancy (1C recommendation). Several studies suggest treatment with one drug (vinca alkaloids or anthracycline preparations), especially in the early stages of HD in pregnancy. But data on the effect of this therapeutic approach is not consistent and describe the possibility of induction of chemotherapy resistance. Hence the question of delay in treatment with chemotherapy until delivery [5, 6] . In the presented patient supradiaphragmal form of disease was diagnosed, without presence of B symptoms with stage II disease, elevated LDH, hypoalbuminemia, and elevated ESR. The patient had no clinical signs of advanced nodal and extranodal disease that could be exacerbated during pregnancy. It was decided not to start the treatment with chemotherapy until delivery. The patient started a therapy with corticosteroids. The clinical monitoring of the disease during pregnancy showed no progression of HD in terms of local diagnosis of the disease. Figure 1 shows the accepted therapeutic algorithm for treatment of HD during pregnancy. From the limited data in the literature it can be concluded that pregnant patients diagnosed with HD in the second and third trimester of pregnancy can safely be treated with chemotherapy and other patients with HD that are not in that situation. For many years it has been believed that pregnancy condition increases the incidence of relapse and mortality in patients with HD. However, the largest study of 48 pregnant women with HD that had been treated with chemotherapy during pregnancy showed 20 years survival, which was identical to the control group of patients with HD who had that condition [7] . Also infants born to mothers with HB had a higher incidence of prematurety and intrauterine retardation of growth and development. There are no data on the metastasis of HD in the placenta or fetus [8] .
Conclusion
HD is a rare condition during pregnancy with many diagnostic and therapeutic limitations in access to treatment. It is necessary to analyze a larger series of pregnant patients with HB in order to obtain more data on the characteristics of the disease during pregnancy. These data will be essential in therapeutic decision about which pregnant women with HB can accommodate disease enabling delay treatment with chemotherapy instead of immediate initiation of treatment.
